Federated Hermes, Inc. Vir Biotechnology, Inc. Transaction History

Federated Hermes, Inc.

$43 Billion
Q4 2024

A detailed history of Federated Hermes, Inc. transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 6,621 shares of VIR stock, worth $63,892. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,621

Previous 51,251 87.08%

Holding current value

$63,892

Previous $383,000 87.47%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$6.74 - $10.17 $300,806 - $453,887	-44,630 Reduced 87.08%	6,621 $48,000
Q3 2024 Nov 13, 2024	SELL	$7.26 - $10.7 $1.81 Million - $2.66 Million	-248,897 Reduced 82.92%	51,251 $383,000
Q2 2024 Aug 08, 2024	BUY	$7.63 - $12.66 $2.28 Million - $3.78 Million	298,603 Added 19327.06%	300,148 $2.67 Million
Q1 2024 May 14, 2024	SELL	$8.6 - $11.9 $45,691 - $63,224	-5,313 Reduced 77.47%	1,545 $15,000
Q4 2023 Jan 31, 2024	BUY	$7.76 - $10.29 $53,218 - $70,568	6,858 New	6,858 $68,000
Q2 2023 Aug 14, 2023	SELL	$23.2 - $27.29 $21,947 - $25,816	-946 Reduced 45.35%	1,140 $27,000
Q1 2023 May 08, 2023	BUY	$22.26 - $30.85 $6,366 - $8,823	286 Added 15.89%	2,086 $48,000
Q4 2022 Feb 13, 2023	SELL	$19.96 - $28.22 $4.71 Million - $6.66 Million	-236,113 Reduced 99.24%	1,800 $45,000
Q3 2022 Nov 14, 2022	BUY	$18.26 - $31.1 $4.34 Million - $7.4 Million	237,913 New	237,913 $4.59 Million
Q2 2022 Aug 15, 2022	SELL	$19.08 - $26.7 $1,411 - $1,975	-74 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$21.19 - $40.01 $1,568 - $2,960	74 New	74 $2,000
Q2 2020 Aug 13, 2020	SELL	$27.89 - $47.86 $726,757 - $1.25 Million	-26,058 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$12.04 - $60.2 $313,738 - $1.57 Million	26,058 New	26,058 $893,000

Others Institutions Holding VIR

# of Institutions

230

Shares Held

90.1M

Call Options Held

1.28M

Put Options Held

235K

View Full List

About Vir Biotechnology, Inc.

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $1.28B
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

More about VIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Vir Biotechnology, Inc. Transaction History